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The Riata series of leads (St Jude Medical) are defibrillator leads with silicone as the insulation material. In December 2010, Riata & Riata ST leads 
were no longer marketed. The manufacturer-quoted lead failure rate at this time was 0.47% over 9 years2. However we observed a 15% failure rate 
in our Riata population at initial fluoroscopic screening in December 20103. This is a follow-up of our Riata Screening programme in N. Ireland.
Methods: All patients from our implant centre with a Riata or Riata ST series lead were identified & invited for screening. High-resolution 
fluoroscopic images in PA & 2 orthogonal planes were taken and lead parameters were checked. These images were subsequently read 
independently by 3 cardiologists for the presence of insulation breach with conductor separation. This was categorised as negative (neg), borderline 
positive (BLP) or positive (pos).
Results: 165 lead were screened last year and a total of 25 lead found to be positive for insulation breach with conductor separation (5 presented 
with spontaneous lead issues and insulation breach was confirmed on fluoroscopy). 139 leads were screened this year - 7 of the original cohort 
had died, 14 did not attend (DNA), 1 was not contactable, 2 were excluded and 2 positive leads had already been extracted. The average interval 
between first and second screening was 239 days. After screening 110 (79%) patients were categorised as neg for insulation breach and conductor 
separation, 3 (2%) were BLP and 26 (19%) were pos. Of these, 5 were new pos since last year; 2 had progressed from a previous BLP appearance 
and 3 from neg. 1 patient who was BLP last year was deemed neg this year. An additional 9 patients who DNA screening last year attended this year. 
Of these, 7 were neg for insulation breach & conductor separation, 2 were pos.
Conclusion: In our Riata population we found a lead failure incidence of 2.6%/year and a prevalence of 19%. This exceeds the manufacturer-
quoted 0.47%. Our data suggests that insulation failure is progressive over time. Therefore interval lead screening by fluoroscopy, in addition to the 
advised lead parameter checks1 is justified. Lead screening programmes & strategies for dealing with lead failure should be developed & agreed.
